SOFOSBUVIR-CONTAINING REGIMEN FOR THE TREATMENT OF HEPATITIS C VIRUS IN A PATIENT WITH SICKLE-THALASSEMIA: THE FIRST CASE REPORT

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

HUSSEIN NAWFAL R.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: International Journal of Infection Year:2017 | Volume:4 | Issue:1 Page(s): 0-0

Download Full-Text

View:

204

Download:

Cites:

Information Journal Paper

Title

SOFOSBUVIR-CONTAINING REGIMEN FOR THE TREATMENT OF HEPATITIS C VIRUS IN A PATIENT WITH SICKLE-THALASSEMIA: THE FIRST CASE REPORT

Author(s)

HUSSEIN NAWFAL R. | Issue Writer Certificate

Keywords

HCV

HEMOGLOBINOPATHY

THALASSEMIA

IRAQ

DAA

SOFOSBUVIR

Abstract

Introduction: Chronic HCV could be treated with classical interferon-containing regimen. However, it was previously shown that the success rate with such a regimen is around 50% in patients with HEMOGLOBINOPATHY and HCV. Although directly acting antivirals (DAAs) are potent for the treatment of HCV, such drugs have not been approved for the treatment of HCV in patients with HEMOGLOBINOPATHY.Case Presentation: We described a 16- year-old male patient with sickle-thalassemia who was infected with a HCV. Treatment was started with SOFOSBUVIR, ribavirin and pegylated interferon and continued for 12 weeks. Rapid virologic response was achieved and liver enzymes decreased gradually. Sustained virologic response was achieved as HCV reverse transcription-polymerase chain reaction (RT-PCR) was negative 12 weeks after stopping treatment. The patient reported no side effect during the course of treatment.Conclusions: If such a regimen is approved, it would be a breakthrough in the treatment of HCV in subjects with HEMOGLOBINOPATHY.More prospective, randomized control trial studies are needed to investigate the efficacy and safety profile of such a regimen.

Cites

No record.

References

No record.

Cite

APA: Copy

HUSSEIN, NAWFAL R.. (2017). SOFOSBUVIR-CONTAINING REGIMEN FOR THE TREATMENT OF HEPATITIS C VIRUS IN A PATIENT WITH SICKLE-THALASSEMIA: THE FIRST CASE REPORT. INTERNATIONAL JOURNAL OF INFECTION, 4(1), 0-0. SID. https://sid.ir/paper/349188/en

Vancouver: Copy

HUSSEIN NAWFAL R.. SOFOSBUVIR-CONTAINING REGIMEN FOR THE TREATMENT OF HEPATITIS C VIRUS IN A PATIENT WITH SICKLE-THALASSEMIA: THE FIRST CASE REPORT. INTERNATIONAL JOURNAL OF INFECTION[Internet]. 2017;4(1):0-0. Available from: https://sid.ir/paper/349188/en

IEEE: Copy

NAWFAL R. HUSSEIN, “SOFOSBUVIR-CONTAINING REGIMEN FOR THE TREATMENT OF HEPATITIS C VIRUS IN A PATIENT WITH SICKLE-THALASSEMIA: THE FIRST CASE REPORT,” INTERNATIONAL JOURNAL OF INFECTION, vol. 4, no. 1, pp. 0–0, 2017, [Online]. Available: https://sid.ir/paper/349188/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops